Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis

Nephrology Dialysis Transplantation

Volumn 29, Issue 11, 2014, Pages 2092-2099

  Wang, Steven ^a   Alfieri, Thomas ^a   Ramakrishnan, Karthik ^a   Braunhofer, Peter ^b   Newsome, Britt A ^c  

^a DAVITA CLINICAL RESEARCH   (United States)

^b Vifor (International) Inc   (Switzerland)

^c Denver Nephrology   (United States)

Author keywords

Adherence; Hemodialysis; Phosphate binders; Pill burden; Retrospective study

Indexed keywords

CALCIUM ACETATE; LANTHANUM CHLORIDE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; CLINICAL ASSESSMENT; CONFERENCE PAPER; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MEDICATION COMPLIANCE; MEDICATION POSSESSION RATIO; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PILL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PHARMACY; PSYCHOLOGY; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; STANDARDS;

FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PHOSPHORUS; QUALITY OF LIFE; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84919838675     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft280     Document Type: Conference Paper

References (28)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
2. Karamanidou C, Clatworthy J,Weinman J et al. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008; 9: 2
3. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
4. Marchais SJ, Metivier F, Guerin AP et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2178-2183
5. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482
6. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
7. Saran R, Bragg-Gresham JL, Rayner HC et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003; 64: 254-262
8. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
9. Menon V, Greene T, Pereira AA et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46: 455-463
10. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396
11. Benner D, Nissenson AR, Van Wyck D. Focused clinical campaign improves mineral and bone disorder outcomes. J Ren Care 2012; 38: 2-8
12. Port FK, Pisoni RL, Bommer J et al. Improving outcomes for dialysis patients in the International Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2006; 1: 246-255
13. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130
14. Toussaint ND, Pedagogos E, Beavis J et al. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant 2011; 26: 1319-1326
15. Weed-Collins M, Hogan R. Knowledge and health beliefs regarding phosphate-binding medication in predicting compliance. ANNA J 1989; 16: 278-282, 285, discussion 286
16. Milas NC, Nowalk MP, Akpele L et al. Factors associated with adherence to the dietary protein intervention in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 1995; 95: 1295-1300
17. Cianciaruso B, Capuano A, D'Amaro E et al. Dietary compliance to a low protein and phosphate diet in patients with chronic renal failure. Kidney Int Suppl 1989; 27: S173-S176
18. Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med 1993; 37: 1035-1043
19. Morduchowicz G, Sulkes J, Aizic S et al. Compliance in hemodialysis patients: a multivariate regression analysis. Nephron 1993; 64: 365-368
20. Arenas MD, Malek T, Alvarez-Ude F et al. Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control. Nefrologia 2010; 30: 522-530
21. Arenas MD, Malek T, Gil MT et al. Challenge of phosphorus control in hemodialysis patients: a problem of adherence?. J Nephrol 2010; 23: 525-534
22. Chiu YW, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089-1096
23. Peterson AM, Nau DP, Cramer JA et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12
24. Leslie R. Calculating Medication Compliance, Adherence and Persistence in Administrative Pharmacy Claims Databases. In Proceedings of the Western Users of SAS Software Meeting. 5-7 November 2008, Universal City, CA, USA.
25. Mehrotra R, Martin KJ, Fishbane S et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008; 3: 1437-1445
26. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Medicare and Medicaid programs; Conditions for coverage for ESRD facilities, Final Rule. Fed Regist 2008; 73: 20370-20484
27. Lindberg M, Lindberg P. Overcoming obstacles for adherence to phosphate binding medication in dialysis patients: a qualitative study. Pharm World Sci 2008; 30: 571-576
28. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310